抗凝治疗与重型COVID-19合并凝血病患者死亡率降低相关
该回顾性研究分析了同济医院449例重型COVID-19患者,比较使用与未使用肝素(主要为低分子肝素)患者的28天死亡率。总体死亡率无差异,但在SOFA诱导凝血病(SIC)评分≥4或D-二聚体>正常上限6倍的患者中,肝素使用者28天死亡率显著低于非使用者。
核心结论
- 以低分子肝素为主的抗凝治疗可能与满足SIC标准或D-二聚体显著升高的重型COVID-19患者预后改善相关。
研究设计与样本
- 回顾性分析同济医院连续纳入的449例重型COVID-19患者,其中99例接受肝素(主要为低分子肝素)治疗7天或以上。
主要发现
- 多因素分析显示D-二聚体、凝血酶原时间和年龄与28天死亡率正相关,血小板计数负相关。
关键数值与推荐
- SIC评分≥4或D-二聚体>正常上限6倍的重型COVID-19患者可能从肝素抗凝治疗中获益。
临床怎么用
- 对重型COVID-19患者应评估SIC评分和D-二聚体水平,对满足SIC标准或D-二聚体显著升高者考虑低分子肝素抗凝治疗。
局限性
- 本研究为单中心回顾性分析,样本量有限,肝素使用非随机分配,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A relatively high mortality of severe coronavirus disease 2019 (COVID-19) is worrying, and the application of heparin in COVID-19 has been recommended by some expert consensus because of the risk of disseminated intravascular coagulation and venous thromboembolism. However, its efficacy remains to be validated. METHODS: Coagulation results, medications, and outcomes of consecutive patients being classified as having severe COVID-19 in Tongji hospital were retrospectively analyzed. The 28-day mortality between heparin users and nonusers were compared, as was a different risk of coagulopathy, which was stratified by the sepsis-induced coagulopathy (SIC) score or D-dimer result. RESULTS: There were 449 patients with severe COVID-19 enrolled into the study, 99 of them received heparin (mainly with low molecular weight heparin) for 7 days or longer. D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, P = .910). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score ≥4 (40.0% vs 64.2%, P = .029), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, P = .017). CONCLUSIONS: Anticoagulant therapy mainly with low molecular weight heparin appears to be associated with better prognosis in severe COVID-19 patients meeting SIC criteria or with markedly elevated D-dimer.
引用
- Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. PMID: 32220112. doi:10.1111/jth.14817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。